Publications by authors named "Szymon Lipiec"
Article Synopsis
- Chronic inflammation from inflammatory bowel disease can lead to colitis-associated colorectal cancer (CACRC), which is linked to oxidative stress and inflammation.
- A study tested a series of gold(III) complexes (TGS 121, 404, 512, 701, 702, and 703) on both cancerous and normal colon cell lines, as well as in a mouse model of CACRC.
- TGS 121, 404, and 702 showed the most promise for reducing tumors and inflammation, suggesting their potential as new treatments for colorectal cancer.
Inflammatory bowel diseases (IBD) and their main representatives, Crohn's disease and ulcerative colitis, are worldwide health-care problems with constantly increasing frequency and still not fully understood pathogenesis. IBD treatment involves drugs such as corticosteroids, derivatives of 5-aminosalicylic acid, thiopurines, and others, with the goal to achieve and maintain remission of the disease. Nowadays, as our knowledge about IBD is continually growing, more specific and effective therapies at the molecular level are wanted.
View Article and Find Full Text PDFArticle Synopsis
- Metal-based cancer treatments like cisplatin can cause serious side effects, leading to the exploration of alternatives such as gold (III) complexes that mimic platinum's properties.
- Our research focused on a novel gold (III) complex, TGS 121, which showed selective toxicity towards cancerous cells with Ras mutations while being non-toxic to healthy cells.
- TGS 121 was found to induce multiple cellular stress responses, inhibit cell migration, and accumulate organelles in cancerous cells, suggesting it has a targeted therapeutic potential in cancer treatment.